Single-arm Phase 2 Study to Examine Pembrolizumab and Concurrent Radiation to Induce an Abscopal Effect in Patients With Previously Treated Carcinoma of Unknown Primary (CUP16-268)

Trial Profile

Single-arm Phase 2 Study to Examine Pembrolizumab and Concurrent Radiation to Induce an Abscopal Effect in Patients With Previously Treated Carcinoma of Unknown Primary (CUP16-268)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2018

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms CUP16-268
  • Most Recent Events

    • 01 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 15 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top